< 生产厂家 价格 >

5-溴-2'-脱氧尿苷

5-溴-2'-脱氧尿苷用途

【用途一】
用于脑瘤和头颈部肿瘤的放射增敏剂，从而提高放疗效果。与抗代谢剂合用亦能提高疗效。
【用途二】
胸腺嘧啶类似物，在遗传学研究中用作诱变剂（mutagen），在细胞分裂的S-期选择性地插进DNA。
点击显示

5-溴-2'-脱氧尿苷名称

[ CAS 号 ]:
59-14-3

[ 中文名 ]:
溴脲苷

[ 英文名 ]:
Broxuridine

[中文别名 ]:

[英文别名 ]:

5-溴-2'-脱氧尿苷生物活性

[ 描述 ]:

5-BrdU是一种核苷类似物,可与胸苷竞争掺入DNA。 5-BrdU通常用于检测增殖细胞。

[ 相关类别 ]:

信号通路 >> 细胞周期/DNA损伤 >> 核苷抗代谢药/类似物
研究领域 >> 其他

[体外研究]

溴脱氧尿苷诱导癌细胞系和癌干细胞群扩增RG2大鼠神经胶质瘤细胞的进行性,剂量响应性抑制。在H9细胞和BJ成纤维细胞中,溴脱氧尿苷改变细胞周期谱[1]。 BrdU稳定整合到DNA中,因此可用于评估细胞增殖和其他细胞过程[2]。

[体内研究]

Bromodeoxyuridine(300 mg/kg,ip或0.8 mg/mL,po)显着减缓大鼠胶质瘤RG2肿瘤模型中的肿瘤进展[1]。

[细胞实验]

最初以2000个细胞/ cm 2接种培养物，并用Z2 Coulter计数器定量。将RG2大鼠神经胶质瘤细胞用0,1,10或50μMBrdU处理24小时，并在18天内获得累积生长曲线。对照和处理的细胞进行定量，并在处理后第5,12和18天以相同的密度重新铺板。

[参考文献]

[1]. Levkoff LH, et al. Bromodeoxyuridine inhibits cancer cell proliferation in vitro and in vivo. Neoplasia. 2008 Aug;10(8):804-16.

[2]. Rothaeusler K, et al. Assessment of cell proliferation by 5-bromodeoxyuridine (BrdU) labeling for multicolor flow cytometry. Curr Protoc Cytom. 2007 Apr;Chapter 7:Unit7.31


[相关活性小分子]

阿扎胞苷 | 盐酸呋咯地辛 | 5-氟-2'-脱氧脲核苷 | 雷替曲塞 | 曲氟尿苷 | 阿糖腺苷 | 盐酸Tipiracil | 克罗拉滨 | 去氧氟尿苷 | 奈拉滨 | 8-氮鸟嘌呤 | 氟环戊烯基胞嘧啶 | 替加氟 | LY2334737 | 氟脲己胺

5-溴-2'-脱氧尿苷物理化学性质

[ 密度 ]:
1.9±0.1 g/cm3

[ 熔点 ]:
191-194 °C (dec.)(lit.)

[ 分子式 ]:
C9H11BrN2O5

[ 分子量 ]:
307.098

[ 精确质量 ]:
305.985138

[ PSA ]:
104.55000

[ LogP ]:
-0.81

[ 外观性状 ]:
白色结晶粉末

[ 折射率 ]:
1.652

[ 储存条件 ]:
库房通风低温干燥

[ 水溶解性 ]:
1-5 g/100 mL at 22 ºC

5-溴-2'-脱氧尿苷MSDS

详细MSDS(安全技术说明书)

5-溴-2'-脱氧尿苷毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :
YU7350000
CHEMICAL NAME :
Uridine, 5-bromo-2'-deoxy-
CAS REGISTRY NUMBER :
59-14-3
BEILSTEIN REFERENCE NO. :
0030395
LAST UPDATED :
199712
DATA ITEMS CITED :
151
MOLECULAR FORMULA :
C9-H11-Br-N2-O5
MOLECULAR WEIGHT :
307.13
WISWESSER LINE NOTATION :
T6NVMVJ EE A- ET5OTJ B1Q CQ

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
8400 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
1500 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
3900 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Cardiac - pulse rate Lungs, Thorax, or Respiration - respiratory depression
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
2320 mg/kg
TOXIC EFFECTS :
Vascular - other changes
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Unreported
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
2300 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
9100 mg/kg
TOXIC EFFECTS :
Behavioral - muscle weakness Blood - changes in spleen Nutritional and Gross Metabolic - weight loss or decreased weight gain
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
3050 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Cardiac - pulse rate Lungs, Thorax, or Respiration - respiratory depression
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
3500 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Cardiac - pulse rate Lungs, Thorax, or Respiration - respiratory depression
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
2500 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Cardiac - pulse rate Lungs, Thorax, or Respiration - respiratory depression
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Bird - quail
DOSE/DURATION :
>100 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
16 mg/kg
TOXIC EFFECTS :
Tumorigenic - Carcinogenic by RTECS criteria Endocrine - thyroid tumors Reproductive - Tumorigenic effects - testicular tumors
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
250 mg/kg
SEX/DURATION :
female 13 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - cytological changes (including somatic cell genetic material)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
200 mg/kg
SEX/DURATION :
female 13 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
500 mg/kg
SEX/DURATION :
female 11 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - respiratory system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
700 mg/kg
SEX/DURATION :
female 9-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - weaning or lactation index (e.g., # alive at weaning per # alive at day 4) Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
600 mg/kg
SEX/DURATION :
female 8-13 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - delayed effects
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
400 mg/kg
SEX/DURATION :
female 9 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
300 mg/kg
SEX/DURATION :
female 10 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
200 mg/kg
SEX/DURATION :
female 8 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - eye/ear
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
200 mg/kg
SEX/DURATION :
female 11 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
400 mg/kg
SEX/DURATION :
female 8 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
DOSE :
40 mg/kg
SEX/DURATION :
female 6 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - other effects to embryo
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Parenteral
DOSE :
300 mg/kg
SEX/DURATION :
female 8 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Parenteral
DOSE :
1200 mg/kg
SEX/DURATION :
female 9 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - cytological changes (including somatic cell genetic material)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Parenteral
DOSE :
600 mg/kg
SEX/DURATION :
female 9 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Parenteral
DOSE :
1 gm/kg
SEX/DURATION :
female 7 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Parenteral
DOSE :
1 gm/kg
SEX/DURATION :
female 10 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
DOSE :
500 mg/kg
SEX/DURATION :
female 11 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
400 mg/kg
SEX/DURATION :
female 8 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
400 mg/kg
SEX/DURATION :
female 10 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
640 mg/kg
SEX/DURATION :
female 8 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
900 mg/kg
SEX/DURATION :
female 9 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - cytological changes (including somatic cell genetic material) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
DOSE :
400 mg/kg
SEX/DURATION :
female 8 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetal death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
DOSE :
400 mg/kg
SEX/DURATION :
female 8 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
DOSE :
400 mg/kg
SEX/DURATION :
female 8 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
TYPE OF TEST :
Specific locus test
TYPE OF TEST :
Sister chromatid exchange
TYPE OF TEST :
Cytogenetic analysis
TYPE OF TEST :
Sister chromatid exchange
TYPE OF TEST :
Sister chromatid exchange
TYPE OF TEST :
Sister chromatid exchange
TYPE OF TEST :
DNA inhibition
TYPE OF TEST :
Sister chromatid exchange
TYPE OF TEST :
Mutation in mammalian somatic cells
TYPE OF TEST :
Sperm Morphology
TYPE OF TEST :
Micronucleus test
TYPE OF TEST :
Cytogenetic analysis
TYPE OF TEST :
Sister chromatid exchange
TYPE OF TEST :
Sister chromatid exchange
TYPE OF TEST :
Sister chromatid exchange
TYPE OF TEST :
Sperm Morphology
TYPE OF TEST :
Sperm Morphology
TYPE OF TEST :
Heritable translocation test
TYPE OF TEST :
Sister chromatid exchange
TYPE OF TEST :
Sperm Morphology
TYPE OF TEST :
Sister chromatid exchange
TYPE OF TEST :
Sister chromatid exchange

MUTATION DATA

TYPE OF TEST :
Sister chromatid exchange
TEST SYSTEM :
Mammal - species unspecified Fibroblast
DOSE/DURATION :
100 umol/L
REFERENCE :
MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964- Volume(issue)/page/year: 254,13,1991 *** REVIEWS *** TOXICOLOGY REVIEW 32XPAD "Teratology," Berry, C.L., and D.E. Poswillo, eds., New York, Springer, 1975 Volume(issue)/page/year: -,49,1975 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X4811 No. of Facilities: 3 (estimated) No. of Industries: 1 No. of Occupations: 1 No. of Employees: 6 (estimated) No. of Female Employees: 3 (estimated)
点击显示

5-溴-2'-脱氧尿苷安全信息

[ 符号 ]:

GHS08

[ 信号词 ]:
Danger

[ 危害声明 ]:
H340-H361

[ 警示性声明 ]:
P201-P281-P308 + P313

[ 个人防护装备 ]:
Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter

[ 危害码 (欧洲) ]:
Xn:Harmful;

[ 风险声明 (欧洲) ]:
R36/37/38;R68

[ 安全声明 (欧洲) ]:
S36/37/39-S26

[ 危险品运输编码 ]:
NONH for all modes of transport

[ WGK德国 ]:
2

[ RTECS号 ]:
YU7350000

5-溴-2'-脱氧尿苷合成路线

详细合成路线

5-溴-2'-脱氧尿苷上下游产品

5-溴-2'-脱氧尿苷上游产品

5-溴-2'-脱氧尿苷下游产品

5-溴-2'-脱氧尿苷文献

Metformin repositioning as antitumoral agent: selective antiproliferative effects in human glioblastoma stem cells, via inhibition of CLIC1-mediated ion current.

Oncotarget 5(22) , 11252-68, (2014)

Epidemiological and preclinical studies propose that metformin, a first-line drug for type-2 diabetes, exerts direct antitumor activity. Although several clinical trials are ongoing, the molecular mec...

Transplantation of enteric neural stem/progenitor cells into the irradiated young mouse hippocampus.

Cell. Transplant. 23(12) , 1657-71, (2015)

Radiotherapy is an effective treatment for brain tumors but often results in cognitive deficits in survivors. Transplantation of embryonic or brain-derived neural stem/progenitor cells (BNSPCs) amelio...

FGFR1 mediates recombinant thrombomodulin domain-induced angiogenesis.

Cardiovasc. Res. 105(1) , 107-17, (2014)

The recombinant epidermal growth factor-like domain plus the serine/threonine-rich domain of thrombomodulin (rTMD23) promotes angiogenesis and accelerates the generation of activated protein C (APC), ...


更多文献

相关化工产品/化学物质：

推荐生产厂家/供应商：

公司名：上海化源生化科技有限公司

区域：上海市普陀区

价格：

联系人：徐经理

产品详情：5-溴-2'-脱氧尿苷

公司名：上海吉至生化科技有限公司

区域：上海市奉贤区

价格：
￥168.0/1g ￥568.0/5g

联系人：刘佳

产品详情：5-溴-2'-脱氧尿苷

公司名：上海源溪生物科技有限公司

区域：上海市浦东新区

价格：
￥需询单/1g

联系人：赖经理

产品详情：Bromodeoxyuridine (BrdU)

公司名：上海脉铂医药科技有限公司

区域：上海市嘉定区

价格：
￥789.0/1g ￥539.0/1g ￥489.0/500mg ￥需询单/1g

联系人：李先生

产品详情：5-BrdU

公司名：上海阿拉丁生化科技股份有限公司

区域：上海市浦东新区

价格：
￥96.9/1g ￥29.9/250mg ￥387.9/5g ￥409.9/1ml

联系人：阿拉丁

产品详情：5-溴-2'-脱氧尿苷(BUdR)

查看所有供应商请点击：

5-溴-2'-脱氧尿苷供应商

相关化合物

本网页内容来自不同专业数据源，如对内容有疑义，欢迎联系service1@chemsrc.com。

【5-溴-2'-脱氧尿苷】化源网提供5-溴-2'-脱氧尿苷CAS号59-14-3，5-溴-2'-脱氧尿苷MSDS及其说明、性质、英文名、生产厂家、作用/用途、分子量、密度、沸点、熔点、结构式等。CAS号查询5-溴-2'-脱氧尿苷上化源网，专业又轻松。>>电脑版：5-溴-2'-脱氧尿苷

标题：5-溴-2'-脱氧尿苷_MSDS_用途_密度_CAS号【59-14-3】_化源网 地址：https://m.chemsrc.com/mip/cas/59-14-3_165464.html